LT626

LT626 is a **small molecule inhibitor** of poly (ADP-ribose) polymerase (PARP), structurally similar to BMN673 (talazoparib). It acts by inhibiting PARP activity, impairing DNA repair, and sensitizing cancer cells to DNA damage. Preclinical studies have shown that LT626 functions as a potent radiosensitizer, synergizing with ionizing radiation to inhibit tumor growth and enhance cell death in lung and pancreatic cancer models. LT626 increases DNA damage biomarkers (γH2AX, 53BP1) and upregulates DNA damage response kinases (ATM, ATR) as part of its mechanism. It has also shown synergy with chemotherapeutic agents like cisplatin, oxaliplatin, and SN-38 in colorectal cancer cell lines[1][2].